CCND1 is altered in 21.26% of mantle cell lymphoma patients [4].

CCND1 Overexpression is an inclusion criterion in 23 clinical trials for mantle cell lymphoma, of which 19 are open and 4 are closed. Of the trials that contain CCND1 Overexpression and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 5 are phase 1 (2 open), 6 are phase 1/phase 2 (6 open), 9 are phase 2 (8 open), and 2 are phase 3 (2 open) [5].

CCND1 is altered in 1.56% of follicular lymphoma patients [4].

CCND1 Overexpression is an inclusion criterion in 6 clinical trials for follicular lymphoma, of which 4 are open and 2 are closed. Of the trials that contain CCND1 Overexpression and follicular lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1 (1 open), and 2 are phase 1/phase 2 (2 open) [5].

CCND1 is altered in 0.58% of diffuse large B-cell lymphoma patients [4].

CCND1 Overexpression is an inclusion criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 2 are closed. Of the trials that contain CCND1 Overexpression and diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 1 (0 open) and 2 are phase 1/phase 2 (2 open) [5].

CCND1 Overexpression is an inclusion criterion in 3 clinical trials for chronic lymphocytic leukemia, of which 3 are open and 0 are closed. Of the trials that contain CCND1 Overexpression and chronic lymphocytic leukemia as inclusion criteria, 3 are phase 1/phase 2 (3 open) [5].

CCND1 Overexpression is an inclusion criterion in 3 clinical trials for marginal zone lymphoma, of which 2 are open and 1 is closed. Of the trials that contain CCND1 Overexpression and marginal zone lymphoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

CCND1 is altered in 3.95% of B-cell non-hodgkin lymphoma patients [4].

CCND1 Overexpression is an inclusion criterion in 2 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CCND1 Overexpression and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

CCND1 Overexpression is an inclusion criterion in 2 clinical trials for lymphoplasmacytic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CCND1 Overexpression and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

CCND1 Overexpression is an inclusion criterion in 2 clinical trials for small lymphocytic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CCND1 Overexpression and small lymphocytic lymphoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

CCND1 is altered in 10.33% of bladder carcinoma patients [4].

CCND1 Overexpression is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Overexpression and bladder carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CCND1 Overexpression is an inclusion criterion in 1 clinical trial for Burkitt lymphoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Overexpression and Burkitt lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CCND1 Overexpression is an inclusion criterion in 1 clinical trial for EBV-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Overexpression and EBV-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CCND1 Overexpression is an inclusion criterion in 1 clinical trial for grade 3b follicular lymphoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Overexpression and grade 3b follicular lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CCND1 Overexpression is an inclusion criterion in 1 clinical trial for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Overexpression and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CCND1 Overexpression is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Overexpression and hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CCND1 Overexpression is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Overexpression and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CCND1 Overexpression is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Overexpression and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CCND1 is altered in 3.14% of non-hodgkin lymphoma patients [4].

CCND1 Overexpression is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Overexpression and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CCND1 Overexpression is an inclusion criterion in 1 clinical trial for primary central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Overexpression and primary central nervous system lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CCND1 Overexpression is an inclusion criterion in 1 clinical trial for T-cell/histiocyte-rich large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Overexpression and T-cell/histiocyte-rich large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CCND1 Overexpression is an inclusion criterion in 1 clinical trial for transformed non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Overexpression and transformed non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CCND1 is altered in 10.61% of urothelial carcinoma patients [4].

CCND1 Overexpression is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Overexpression and urothelial carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CCND1 Overexpression is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Overexpression and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 1 (1 open) [5].